Glancy
Binkow & Goldberg LLP announces that a class action lawsuit has
been filed in the United States District Court for the Southern District
of Florida on behalf of a class (the “Class”) comprising all purchasers
of the securities of Catalyst
Pharmaceutical Partners, Inc. (“Catalyst” or the “Company”)
(NASDAQ:CPRX) between October 31, 2012 and October 18, 2013, inclusive
(the “Class Period”).
A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY
BINKOW & GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT (888) 773-9224, OR
AT (212) 682-5340, OR BY EMAIL TO SHAREHOLDERS@GLANCYLAW.COM
TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR
MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
Catalyst operates as a development-stage specialty pharmaceutical
company, focused on the development and commercialization of novel
prescription drugs targeting rare neuromuscular and neurological
diseases and disorders. One of the Company’s principal products is
Firdapse, purportedly in Phase III clinical trials for treatment of
Lambert-Eaton Myasthenic Syndrome (LEMS), a rare and sometimes fatal
autoimmune disease characterized by muscle weakness. The Complaint
alleges that the defendants failed to disclose that one of Catalyst’s
competitors – a private pharmaceutical company – has been manufacturing
a drug biologically equivalent to Firdapse, and providing it to patients
with LEMS, free of charge, through a compassionate use program. On
October 18, 2013, an article published by The Street stated that
Catalyst’s Firdapse was the same drug that its competitor has been
manufacturing and providing in the U.S. for at least two decades.
If you are a member of the Class described above you may move the Court
no later than December 24, 2013, to serve as lead plaintiff; however,
you must meet certain legal requirements. If you wish to learn
more about this action, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2013